Myeloid Leukemia is a type of leukemia affecting myeloid tissues. This disease is a clonal disorder caused by malignant transformation of a bone marrow-derived, self-renewing stem cell or progenitor. This leads to a decreased rate of self-destruction and aberrant differentiation causing an accumulation in the organs and bone marrow by these myeloid cells. The development of Myeloid Leukemia has been associated with many predisposition syndromes that are caused by chromosomal imbalances, DNA repair defects, altered protein synthesis and altered cytokine receptors or signal transduction pathways. Myreloid Leukemia is most often categorized as either Acute or Chronic Myeloid Leukemia.
Myeloid Leukemia Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Myeloid Leukemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 2797 products for the study of Myeloid Leukemia that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Myeloid Leukemia is also known as myeloid leukemia, other myeloid leukemia, myeloid leukemia, no icd-o subtype (morphologic abnormality), unspecified myeloid leukemia without mention of remission, other myeloid leukemia nos (morphologic abnormality), other myeloid leukemia without mention of remission, myeloid leukemia, nos, without mention of remission, other myeloid leukemia (morphologic abnormality), myeloid leukemias (morphologic abnormality), unspecified myeloid leukemia in remission, myeloid leukemia in remission (disorder), other myeloid leukemia nos (disorder), myeloid leukemia, disease (disorder), other myeloid leukemia in remission, other myeloid leukemia (disorder), myelogenous leukemia in remission, myeloid leukemia nos (disorder), myeloid granulocytic leukemia, myeloid leukaemia (category), myeloid leukemia (disorder), myeloid leukemia, disease, non-lymphocytic leukemia, leukemia myelogenous, myelogenous leukemia, myeloid leukaemia, leukemia, myeloid, leukemia.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.